Re-bleeding and all-cause mortality risk in non-variceal upper gastrointestinal bleeding: focusing on patients receiving oral anticoagulant therapy

References

• Yang HJ. Management of peptic ulcer bleeding in patients taking aspirin or anticoagulant. Korean J Gastroenterol. 2020;76(5):1–13. doi: 10.4166/kjg.2020.138.
   Google Scholar
• Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327(20):1406–1412. doi: 10.1056/NEJM199211123272002.
   PubMed Web of Science ®Google Scholar
• Das AK, Willcoxson PD, Corrado OJ, et al. The impact of long-term warfarin on the quality of life of elderly people with atrial fibrillation. Age Ageing. 2007;36(1):95–97. doi: 10.1093/ageing/afl062.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Kardiol Pol. 2016;74(12):1359–1469. doi: 10.5603/KP.2016.0172.
   PubMedGoogle Scholar
• Lanas Á, Carrera-Lasfuentes P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015;13(5):906–912. e2. doi: 10.1016/j.cgh.2014.11.007.
   PubMed Web of Science ®Google Scholar
• Diener H-C. Preventing major gastrointestinal bleeding in elderly patients. Lancet. 2017;390(10093):435–437. doi: 10.1016/S0140-6736(17)31507-6.
   PubMed Web of Science ®Google Scholar
• Li L, Geraghty OC, Mehta Z, et al. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390(10093):490–499. doi: 10.1016/S0140-6736(17)30770-5.
   PubMed Web of Science ®Google Scholar
• Radaelli F, Dentali F, Repici A, et al. Management of anticoagulation in patients with acute gastrointestinal bleeding. Dig Liver Dis. 2015;47(8):621–627. doi: 10.1016/j.dld.2015.03.029.
   PubMedGoogle Scholar
• Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the international consensus group. Ann Intern Med. 2019;171(11):805–822. doi: 10.7326/M19-1795.
   PubMed Web of Science ®Google Scholar
• Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med. 1994;331(11):717–727. doi: 10.1056/NEJM199409153311107.
   PubMed Web of Science ®Google Scholar
• Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am J Gastroenterol. 2007;102(2):290–296. doi: 10.1111/j.1572-0241.2006.00969.x.
   PubMed Web of Science ®Google Scholar
• Travis AC, Wasan SK, Saltzman JR. Model to predict rebleeding following endoscopic therapy for non‐variceal upper gastrointestinal hemorrhage. J Gastroenterol Hepatol. 2008;23(10):1505–1510. doi: 10.1111/j.1440-1746.2008.05594.x.
   PubMed Web of Science ®Google Scholar
• Hong MJ, Lee S-Y, Kim JH, et al. Rebleeding after initial endoscopic hemostasis in peptic ulcer disease. J Korean Med Sci. 2014;29(10):1411–1415. doi: 10.3346/jkms.2014.29.10.1411.
   PubMed Web of Science ®Google Scholar
• Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427(6974):537–541. doi: 10.1038/nature02214.
   PubMed Web of Science ®Google Scholar
• Kwon S, Lee S-R, Choi E-K, et al. Non–vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and prior gastrointestinal bleeding. Stroke. 2021;52(2):511–520. doi: 10.1161/STROKEAHA.120.030761.
   PubMed Web of Science ®Google Scholar
• Lee H-J, Kim H-K, Kim B-S, et al. Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy. PLoS One. 2021;16(6):e0253310. doi: 10.1371/journal.pone.0253310.
   PubMed Web of Science ®Google Scholar
• Pae JY, Kim ES, Kim SK, et al. Gastrointestinal bleeding risk of non-vitamin K antagonist oral anticoagulants versus warfarin in general and after polypectomy: a population-based study with propensity score matching analysis. Intest Res. 2022;20(4):482–494. doi: 10.5217/ir.2021.00161.
   PubMed Web of Science ®Google Scholar
• Radadiya D, Devani K, Brahmbhatt B, et al. Major gastrointestinal bleeding risk with direct oral anticoagulants: does type and dose matter?–a systematic review and network meta-analysis. Eur J Gastroenterol Hepatol. 2021;33(1S Suppl 1):e50–e8. doi: 10.1097/MEG.0000000000002035.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Kohli P. Danger ahead: watch out for indirect comparisons. J Am Coll Cardiol. 2012;60(8):747–748. doi: 10.1016/j.jacc.2012.05.012.
   PubMed Web of Science ®Google Scholar
• Hawkins NM, Er L, Sandhu RK, et al. Validity of different dose reduction criteria for apixaban. Am Heart J. 2021;238:12–15. doi: 10.1016/j.ahj.2021.03.004.
   PubMed Web of Science ®Google Scholar
• Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs. 2014;74(11):1209–1231. doi: 10.1007/s40265-014-0261-1.
   PubMed Web of Science ®Google Scholar
• Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29(7 Suppl):S24–S33. doi: 10.1016/j.cjca.2013.04.002.
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): european society of gastrointestinal endoscopy (ESGE) guideline–update 2021. Endoscopy. 2021;53(3):300–332. doi: 10.1055/a-1369-5274.
   PubMedGoogle Scholar
• Wilkins T, Khan N, Nabh A, et al. Diagnosis and management of upper gastrointestinal bleeding. Am Fam Physician. 2012;85(5):469–476.
   Google Scholar
• Sung JJ, Chiu PW, Chan FK, et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut. 2018;67(10):1757–1768. doi: 10.1136/gutjnl-2018-316276.
   PubMed Web of Science ®Google Scholar
• Oakland K. Changing epidemiology and etiology of upper and lower gastrointestinal bleeding. Best Pract Res Clin Gastroenterol. 2019;42-43:101610. doi: 10.1016/j.bpg.2019.04.003.
   PubMed Web of Science ®Google Scholar
• Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014;63(9):891–900. doi: 10.1016/j.jacc.2013.11.013.
   PubMedGoogle Scholar
• Aisenberg J, Chatterjee-Murphy P, Friedman Flack K, et al. Gastrointestinal bleeding with edoxaban versus warfarin: results from the ENGAGE AF-TIMI 48 trial (effective anticoagulation with factor Xa next generation in atrial fibrillation–thrombolysis in myocardial infarction). Circ Cardiovasc Qual Outcomes. 2018;11(5):e003998. doi: 10.1161/CIRCOUTCOMES.117.003998.
   PubMed Web of Science ®Google Scholar
• Desai J, Kolb JM, Weitz JI, et al. Gastrointestinal bleeding with the new oral anticoagulants–defining the issues and the management strategies. Thromb Haemost. 2013;110(2):205–212. doi: 10.1160/TH13-02-0150.
   PubMed Web of Science ®Google Scholar
• Larssen L, Moger T, Atle Bjørnbeth B, et al. Transcatheter arterial embolization in the management of bleeding duodenal ulcers: a 5.5-year retrospective study of treatment and outcome. Scand J Gastroenterol. 2008;43(2):217–222. doi: 10.1080/00365520701676443.
   PubMed Web of Science ®Google Scholar
• Rockall T, Logan R, Devlin H, et al. Risk assessment after acute upper gastrointestinal haemorrhage. Gut. 1996;38(3):316–321. doi: 10.1136/gut.38.3.316.
   PubMed Web of Science ®Google Scholar
• Strate LL, Saltzman JR, Ookubo R, et al. Validation of a clinical prediction rule for severe acute lower intestinal bleeding. Am J Gastroenterol. 2005;100(8):1821–1827. doi: 10.1111/j.1572-0241.2005.41755.x.
   PubMed Web of Science ®Google Scholar
• Aoki T, Nagata N, Shimbo T, et al. Development and validation of a risk scoring system for severe acute lower gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2016;14(11):1562–1570.e2. doi: 10.1016/j.cgh.2016.05.042.
   PubMed Web of Science ®Google Scholar
• Stanley AJ, Laine L, Dalton HR, et al. Comparison of risk scoring systems for patients presenting with upper gastrointestinal bleeding: international multicentre prospective study. BMJ. 2017;356:i6432. doi: 10.1136/bmj.i6432.
   PubMed Web of Science ®Google Scholar
• Drosdowsky A, Gough K. The charlson comorbidity index: problems with use in epidemiological research. J Clin Epidemiol. 2022;148:174–177. doi: 10.1016/j.jclinepi.2022.03.022.
   PubMed Web of Science ®Google Scholar
• Green FW, Jr, Kaplan MM, Curtis LE, et al. Effect of acid and pepsin on blood coagulation and platelet aggregation: a possible contributor to prolonged gastroduodenal mucosal hemorrhage. Gastroenterology. 1978;74(1):38–43. doi: 10.1016/0016-5085(78)90352-9.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Mori Y, Okamoto H, et al. Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects‐a randomised open‐label cross‐over study. Aliment Pharmacol Ther. 2015;42(6):719–730. doi: 10.1111/apt.13325.
   PubMed Web of Science ®Google Scholar
• Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP 2C19 genotype. Aliment Pharmacol Ther. 2016;43(10):1048–1059. doi: 10.1111/apt.13588.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Furuta T, Fujiwara Y, et al. Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study). Aliment Pharmacol Ther. 2020;51(5):534–543. doi: 10.1111/apt.15641.
   PubMed Web of Science ®Google Scholar
• Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers–results from two phase 3, non‐inferiority randomised controlled trials. Aliment Pharmacol Ther. 2017;45(2):240–252. doi: 10.1111/apt.13876.
   PubMed Web of Science ®Google Scholar
• Tsujita K, Deguchi H, Uda A, et al. Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: a nationwide database study. J Cardiol. 2020;76(1):51–57. doi: 10.1016/j.jjcc.2020.02.012.
   PubMedGoogle Scholar
• Tung C-F, Chow W-K, Chang C-S, et al. The prevalence and significance of hypoalbuminemia in non-variceal upper gastrointestinal bleeding. Hepato-gastroenterology. 2007;54(76):1153–1156.
   PubMedGoogle Scholar
• Kim JS, Kim B-W, Park SM, et al. Factors associated with rebleeding in patients with peptic ulcer bleeding: analysis of the korean peptic ulcer bleeding (K-PUB) study. Gut Liver. 2018;12(3):271–277. doi: 10.5009/gnl17138.
   PubMed Web of Science ®Google Scholar
• Sung JJ, Tsoi KK, Ma TK, et al. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am J Gastroenterol. 2010;105(1):84–89. doi: 10.1038/ajg.2009.507.
   PubMed Web of Science ®Google Scholar
• Lau JY, Sung J, Hill C, et al. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion. 2011;84(2):102–113. doi: 10.1159/000323958.
   PubMed Web of Science ®Google Scholar